{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:28:40Z","timestamp":1789788520690,"version":"4.0.1"},"update-to":[{"DOI":"10.1371\/journal.ppat.1012116","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000}}],"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2022YFC2303403"],"award-info":[{"award-number":["2022YFC2303403"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32171428"],"award-info":[{"award-number":["32171428"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82225021"],"award-info":[{"award-number":["82225021"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAS Project for Young Scientists in Basic Research","award":["YSBR-010"],"award-info":[{"award-number":["YSBR-010"]}]},{"name":"Youth Innovation Promotion Association of the CAS","award":["Y2022037"],"award-info":[{"award-number":["Y2022037"]}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, continues to mutate and generates new variants with increasingly severe immune escape, urging the upgrade of COVID-19 vaccines. Here, based on a similar dimeric RBD design as our previous ZF2001 vaccine, we developed a novel broad-spectrum COVID-19 mRNA vaccine, SWIM516, with chimeric Delta-BA.2 RBD dimer delivered by lipopolyplex (LPP). Unlike the popular lipid nanoparticle (LNP), this LPP-delivered mRNA expresses only in the injection site, which avoids potential toxicity to the liver. We demonstrated the broad-spectrum humoral and cellular immunogenicity of this vaccine to Delta and Omicron sub-variants in na\u00efve mice and as booster shots. When challenged with Delta or Omicron live virus, vaccinated human angiotensin-converting enzyme (hACE2) transgenic mice and rhesus macaques were both protected, displaying significantly reduced viral loads and markedly relieved pathological damages. We believe the SWIM516 vaccine qualifies as a candidate for the next-generation broad-spectrum COVID-19 vaccine.<\/jats:p>","DOI":"10.1371\/journal.ppat.1012116","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T17:49:26Z","timestamp":1711993766000},"page":"e1012116","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Broad-spectrum Delta-BA.2 tandem-fused heterodimer mRNA vaccine delivered by lipopolyplex"],"prefix":"10.1371","volume":"20","author":[{"given":"Pei","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanfan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifa","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3869-615X","authenticated-orcid":true,"given":"George Fu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,4,1]]},"reference":[{"issue":"10","key":"ppat.1012116.ref001","article-title":"Science-based COVID-19 vaccine development","volume":"8","author":"GF Gao","year":"2021","journal-title":"Natl Sci Rev"},{"issue":"10","key":"ppat.1012116.ref002","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/intimm\/dxab061","article-title":"Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021","volume":"33","author":"K Xu","year":"2021","journal-title":"Int Immunol"},{"issue":"12","key":"ppat.1012116.ref003","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/intimm\/dxac031","article-title":"Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021","volume":"34","author":"K Xu","year":"2022","journal-title":"Int Immunol"},{"issue":"3","key":"ppat.1012116.ref004","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","article-title":"SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses","volume":"185","author":"W Dejnirattisai","year":"2022","journal-title":"Cell"},{"issue":"7898","key":"ppat.1012116.ref005","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Y Cao","year":"2022","journal-title":"Nature"},{"key":"ppat.1012116.ref006","article-title":"Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1\/BA.1.1\/BA.2\/BA.3","author":"M Huang","year":"2022","journal-title":"Immunity"},{"issue":"4","key":"ppat.1012116.ref007","doi-asserted-by":"crossref","first-page":"100991","DOI":"10.1016\/j.xcrm.2023.100991","article-title":"An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB","volume":"4","author":"Q He","year":"2023","journal-title":"Cell Rep Med"},{"issue":"16","key":"ppat.1012116.ref008","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant","volume":"386","author":"N Andrews","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"ppat.1012116.ref009","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41591-022-01753-y","article-title":"Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants","volume":"28","author":"HF Tseng","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"ppat.1012116.ref010","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMc2119270","article-title":"Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa","volume":"386","author":"S Collie","year":"2022","journal-title":"N Engl J Med"},{"key":"ppat.1012116.ref011","article-title":"A bivalent Omicron-containing booster vaccine against Covid-19","author":"S Chalkias","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"ppat.1012116.ref012","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41591-022-02092-8","article-title":"Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice","volume":"29","author":"SM Scheaffer","year":"2023","journal-title":"Nat Med"},{"key":"ppat.1012116.ref013","article-title":"Antibody response to Omicron BA.4-BA.5 bivalent booster","author":"Q Wang","year":"2023","journal-title":"N Engl J Med"},{"key":"ppat.1012116.ref014","article-title":"Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent vaccine","author":"J Zou","year":"2023","journal-title":"N Engl J Med"},{"key":"ppat.1012116.ref015","doi-asserted-by":"crossref","first-page":"1051576","DOI":"10.3389\/fimmu.2022.1051576","article-title":"A novel mRNA vaccine, SYS6006, against SARS-CoV-2","volume":"13","author":"K Xu","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"ppat.1012116.ref016","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","article-title":"A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS","volume":"182","author":"L Dai","year":"2020","journal-title":"Cell"},{"issue":"22","key":"ppat.1012116.ref017","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa2202261","article-title":"Efficacy and safety of the RBD-dimer-based Covid-19 vaccine ZF2001 in adults","volume":"386","author":"L Dai","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"ppat.1012116.ref018","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"21","author":"S Yang","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"13","key":"ppat.1012116.ref019","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.cell.2022.04.029","article-title":"Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2","volume":"185","author":"K Xu","year":"2022","journal-title":"Cell"},{"issue":"11","key":"ppat.1012116.ref020","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41422-022-00720-z","article-title":"mRNA vaccines expressing homo-prototype\/Omicron and hetero-chimeric RBD-dimers against SARS-CoV-2","volume":"32","author":"Y Han","year":"2022","journal-title":"Cell Res"},{"issue":"2","key":"ppat.1012116.ref021","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bsheal.2023.02.002","article-title":"Rapid evaluation of heterologous chimeric RBD-dimer mRNA vaccine for currently-epidemic Omicron sub-variants as booster shot after inactivated vaccine","volume":"5","author":"Q Chen","year":"2023","journal-title":"Biosaf Health"},{"key":"ppat.1012116.ref022","doi-asserted-by":"crossref","first-page":"100746","DOI":"10.1016\/j.eclinm.2021.100746","article-title":"mRNA vaccines: A matter of delivery","volume":"32","author":"Y Cao","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"1","key":"ppat.1012116.ref023","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/ID9.0000000000000074","article-title":"Lipid-based poly(I:C) adjuvants strongly enhance the immunogenicity of SARS-CoV-2 receptor-binding domain vaccine","volume":"3","author":"Y Wu","year":"2023","journal-title":"Infectious Diseases & Immunity"},{"issue":"12","key":"ppat.1012116.ref024","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"X Hou","year":"2021","journal-title":"Nature Reviews Materials"},{"issue":"3","key":"ppat.1012116.ref025","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.matt.2021.12.022","article-title":"Oral mRNA delivery using capsule-mediated gastrointestinal tissue injections.","volume":"5","author":"A Abramson","year":"2022","journal-title":"Matter"},{"issue":"7830","key":"ppat.1012116.ref026","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"KS Corbett","year":"2020","journal-title":"Nature"},{"issue":"27","key":"ppat.1012116.ref027","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"FP Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"ppat.1012116.ref028","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.biomaterials.2017.02.019","article-title":"Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination","volume":"125","author":"S Persano","year":"2017","journal-title":"Biomaterials"},{"issue":"1","key":"ppat.1012116.ref029","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-021-00634-z","article-title":"A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity","volume":"6","author":"R Yang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"ppat.1012116.ref030","article-title":"Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis","author":"Y Pan","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"ppat.1012116.ref031","article-title":"IgG4 antibodies induced by repeated vaccination may generate immune tolerance to the SARS-CoV-2 spike protein","volume":"11","author":"VN Uversky","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"ppat.1012116.ref032","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.cell.2020.06.010","article-title":"Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment","volume":"182","author":"J Sun","year":"2020","journal-title":"Cell"},{"issue":"1","key":"ppat.1012116.ref033","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.chom.2020.05.020","article-title":"A mouse model of SARS-CoV-2 infection and pathogenesis","volume":"28","author":"SH Sun","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"7902","key":"ppat.1012116.ref034","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41586-022-04479-6","article-title":"SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo","volume":"603","author":"KPY Hui","year":"2022","journal-title":"Nature"},{"issue":"9","key":"ppat.1012116.ref035","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMc2119426","article-title":"Effects of a prolonged booster interval on neutralization of Omicron variant","volume":"386","author":"X Zhao","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"ppat.1012116.ref036","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1056\/NEJMc2206900","article-title":"Omicron SARS-CoV-2 neutralization from inactivated and ZF2001 vaccines","volume":"387","author":"X Zhao","year":"2022","journal-title":"N Engl J Med"},{"issue":"7948","key":"ppat.1012116.ref037","first-page":"521","article-title":"Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution","volume":"614","author":"Y Cao","year":"2023","journal-title":"Nature"},{"issue":"7","key":"ppat.1012116.ref038","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"A Akinc","year":"2010","journal-title":"Mol Ther"},{"key":"ppat.1012116.ref039","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jconrel.2024.01.002","article-title":"An inoculation site-retained mRNA vaccine induces robust immune responses against SARS-CoV-2 variants","volume":"366","author":"L Huang","year":"2024","journal-title":"J Control Release"},{"key":"ppat.1012116.ref040","doi-asserted-by":"crossref","first-page":"104586","DOI":"10.1016\/j.ebiom.2023.104586","article-title":"Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial","volume":"91","author":"YZ Gui","year":"2023","journal-title":"EBioMedicine"},{"key":"ppat.1012116.ref041","doi-asserted-by":"crossref","first-page":"102372","DOI":"10.1016\/j.eclinm.2023.102372","article-title":"Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos)","volume":"67","author":"Y Fang","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ppat.1012116.ref042","article-title":"Safety and immunogenicity of SW-BIC-213, a modified COVID-19 Lipo-Polyplex mRNA vaccine, in Laotian healthy adults aged 18 years and above: a Phase 1\/2 trial","author":"Y Chen","year":"2023","journal-title":"medRxiv"}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1012116","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1012116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T20:24:25Z","timestamp":1712867065000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1012116"}},"subtitle":[],"editor":[{"given":"Sonja M.","family":"Best","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1012116","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.ppat.1012116","asserted-by":"object"}]},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}